Motif Neurotech develops minimally invasive brain implants designed to treat treatment-resistant depression through targeted neural stimulation. The company’s platform, referred to as DOT, is engineered to operate without an implanted battery, reducing device size and surgical burden. Its implants are designed for precise placement within specific brain circuits implicated in mood regulation. Motif Neurotech positions its technology within regulated clinical development pathways.

The technology delivers wireless electrical stimulation to targeted brain regions using externally powered implants. By eliminating the need for an internal battery, the system enables a smaller implant footprint and supports minimally invasive implantation approaches. Stimulation parameters are designed to be programmable and adaptable to individual patient needs. This approach focuses on durable neuromodulation while minimizing long-term implant complexity.

Motif Neurotech targets patients with depression who have not responded to conventional treatments such as medication or psychotherapy. The platform is intended for use within specialized clinical settings under professional supervision. Its positioning reflects broader efforts to make implantable neuromodulation therapies safer, less invasive, and more accessible for psychiatric indications.